Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. References

  1. American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. Updated 2023. Accessed June 14, 2024. https://www.hcvguidelines.org/
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; 2024. Available at: http://www.clinicalpharmacology.com. Accessed June 14, 2024.
  3. Ribavirin oral capsules package insert. Aurobindo Pharma Limited. July 2023.
  4. Elbasvir/grazoprevir (Zepatier) package insert. Merck Sharp & Dohme, LLC. May 2022.
  5. Glecaprevir/pibrentasvir (Mavyret™) package insert. AbbVie Inc. October 2023.
  6. Ledipasvir and sofosbuvir (Harvoni) package insert. Gilead Sciences, Inc. March 2020.
  7. Sofosbuvir/velpatasvir (Epclusa) package insert. Gilead Sciences, Inc. April 2022.
  8. Sofosbuvir (Sovaldi) package insert. Gilead Sciences, Inc. March 2020.
  9. Peginterferon alfa-2A (Pegasys) package insert. Pharmaand GmbH. December 2023.
  10. Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) package insert. Gilead Sciences, Inc. November 2019.
  11. Bhattacharya D, Aronsohn A, Price J, Lo Re V. The American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel , Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America recommendations for testing, managing, and treating Hepatitis C Virus infection, Clin Infect Dis, 2023;, ciad319, https://doi.org/10.1093/cid/ciad319.